{"id":"W3039432873","doi":"10.1016/j.lungcan.2020.06.032","title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Ignyta; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; MacroGenics; Juno Therapeutics; Pfizer; Incyte; Kite Pharma; Spectrum Pharmaceuticals; Yuhan; Merck KGaA; Regeneron Pharmaceuticals; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Tolerability; Oncology; Cohort; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001053211,0.0001644149,0.0003172321,0.00002828986,0.0001705681,0.00001960239,0.00007094823,0.0000353928,0.0001651249],"category_scores_gemma":[0.00004425452,0.0000968263,0.00005022311,0.0001532183,0.00003330918,0.0000901847,0.0000489055,0.0001289977,0.000002079948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001473077,"about_ca_system_score_gemma":0.0002237716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004374394,"about_ca_topic_score_gemma":0.001673475,"domain_scores_codex":[0.9989905,0.00003654865,0.0002579062,0.0003151082,0.0001661792,0.0002337337],"domain_scores_gemma":[0.9995229,0.00007886281,0.00006890373,0.0001696978,0.00005829185,0.0001013815],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1680006,0.01396367,0.4067583,0.002758316,0.007655249,0.001152865,0.07735191,0.005057893,0.004841517,0.002576687,0.03043034,0.2794526],"study_design_scores_gemma":[0.4014795,0.02742528,0.25345,0.001326492,0.007390874,0.00006089416,0.005760592,0.05202652,0.0008261818,0.0002973502,0.2483763,0.001579971],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796407,0.00111105,0.0003099147,0.01554922,0.0002725291,0.002548205,0.000144579,0.00004740856,0.0003763956],"genre_scores_gemma":[0.995663,0.0003808729,0.0002026556,0.001505143,0.000246962,0.0003926195,0.00007371939,0.00002672142,0.001508303],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2778727,"threshold_uncertainty_score":0.3948462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356613840783815,"score_gpt":0.387555711866924,"score_spread":0.3539895734590858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}